1-7 of 7
Jennifer M. Specht
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies

Carla A. Jaeger-Ruckstuhl, Jennifer M. Specht, Jenna M. Voutsinas, Hugh R. MacMillan, Qian (Vicky) Wu, Vishaka Muhunthan, Carolina Berger, Shalini Pullarkat, Jocelyn H. Wright, Cecilia C.S. Yeung, Teresa S. Hyun, Brandon Seaton, Lauri D. Aicher, Xiaoling Song, Robert H. Pierce, Yun Lo, Gabriel O. Cole, Sylvia M. Lee, Evan W. Newell, David G. Maloney, Stanley R. Riddell
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (3): 503–514.
https://doi.org/10.1158/1078-0432.CCR-24-2172
Published: 03 February 2025
View article titled, Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Open the PDF for Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer

Eve T. Rodler, Brenda F. Kurland, Melissa Griffin, Julie R. Gralow, Peggy Porter, Rosa F. Yeh, Vijayakrishna K. Gadi, Jamie Guenthoer, Jan H. Beumer, Larissa Korde, Sandra Strychor, Brian F. Kiesel, Hannah M. Linden, John A. Thompson, Elizabeth Swisher, Xiaoyu Chai, Stacie Shepherd, Vincent Giranda, Jennifer M. Specht
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2855–2864.
https://doi.org/10.1158/1078-0432.CCR-15-2137
Published: 14 June 2016
View article titled, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or <em>BRCA</em> Mutation–Associated Breast Cancer
Open the PDF for Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or <em>BRCA</em> Mutation–Associated Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004

George Somlo, Francesco Atzori, Lewis C. Strauss, William J. Geese, Jennifer M. Specht, William J. Gradishar, Alissa Rybicki, Oumar Sy, Linda T. Vahdat, Javier Cortes
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1884–1893.
https://doi.org/10.1158/1078-0432.CCR-12-0652
Published: 02 April 2013
View article titled, Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004
Open the PDF for Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 in another window
Includes: Supplementary data
Journal Articles

Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer

Hannah M. Linden, Brenda F. Kurland, Lanell M. Peterson, Erin K. Schubert, Julie R. Gralow, Jennifer M. Specht, Georgiana K. Ellis, Thomas J. Lawton, Robert B. Livingston, Philip H. Petra, Jeanne M. Link, Kenneth A. Krohn, David A. Mankoff
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (14): 4799–4805.
https://doi.org/10.1158/1078-0432.CCR-10-3321
Published: 17 July 2011
View article titled, Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer
Open the PDF for Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake

Lisa K. Dunnwald, Robert K. Doot, Jennifer M. Specht, Julie R. Gralow, Georgiana K. Ellis, Robert B. Livingston, Hannah M. Linden, Vijayakrishna K. Gadi, Brenda F. Kurland, Erin K. Schubert, Mark Muzi, David A. Mankoff
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2400–2409.
https://doi.org/10.1158/1078-0432.CCR-10-2649
Published: 14 April 2011
View article titled, PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake
Open the PDF for PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake in another window
Journal Articles

Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer

Jennifer M. Specht, Brenda F. Kurland, Susan K. Montgomery, Lisa K. Dunnwald, Robert K. Doot, Julie R. Gralow, Georgina K. Ellis, Hannah M. Linden, Robert B. Livingston, Kimberly H. Allison, Erin K. Schubert, David A. Mankoff
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (10): 2803–2810.
https://doi.org/10.1158/1078-0432.CCR-10-0026
Published: 13 May 2010
View article titled, Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer
Open the PDF for Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer in another window
Journal Articles

Blood Flow-Metabolism Mismatch: Good for the Tumor, Bad for the Patient

David A. Mankoff, Lisa K. Dunnwald, Savannah C. Partridge, Jennifer M. Specht
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (17): 5294–5296.
https://doi.org/10.1158/1078-0432.CCR-09-1448
Published: 31 August 2009
View article titled, Blood Flow-Metabolism Mismatch: Good for the Tumor, Bad for the Patient
Open the PDF for Blood Flow-Metabolism Mismatch: Good for the Tumor, Bad for the Patient in another window
Includes: Supplementary data